InflaRx N.V. (IFRX) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 129.0% versus a gain of 13.0%. Over five years, IFRX leads with a -36.8% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($231.8 million vs $229.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | IPSC |
|---|---|---|
| Share price | $1.56 | $1.28 |
| Market cap | $229.89M | $231.78M |
| 1-day change | -1.27% | -3.03% |
| YTD return | +54.46% | +28.64% |
| 1-year return | +13.04% | +128.98% |
| 5-year return | -36.84% | -93.37% |
| EPS (TTM) | $-0.58 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $3.04 |
| 52-week low | $0.798 | $0.435 |
| Distance from 52-week high | -47.10% | -57.89% |
| Analyst consensus | none | buy |
| Avg. price target upside | +391.03% | +271.09% |
| Average volume | 794.10K | 649.61K |
| Shares outstanding | 147.37M | 181.08M |
| Employees | 65 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed IFRX by 115.9 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
IFRX vs IPSC FAQ
Which is bigger, InflaRx N.V. or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $229.89M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or IPSC?
IPSC returned +128.98% over the past 12 months, compared with +13.04% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Century Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for InflaRx N.V. and Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics.